Deputy Minister Of SOEs Will Brush Up Management That Makes Indofarma Lose

Deputy Minister of State-Owned Enterprises (BUMN) Kartika Wirjoatmodjo. (Mery Handayani/VOI)

JAKARTA - PT Indofarma Tbk (INAF) is currently in the public spotlight recently shrinking the findings of the Supreme Audit Agency (BPK) regarding the potential fraud or fraud that occurred in the company.

Deputy Minister of SOEs Kartika Wirjoatmodjo said that his party is currently taking legal action against the case.

This is in line with the findings of the BPK and was reported to the Attorney General's Office (AGO).

"Yes, if our Indofarma is indeed taking a legal approach. So it is in accordance with the findings of the BPK and the Prosecutor's Office," he said when met at JCC, Jakarta, Thursday, June 20.

The man who is familiarly called Tiko said that his party would not be indiscriminate in the legal process.

Including if problematic company administrators are found.

"Yes, we respect the law and we will take firm action against the problematic management," he said.

As previously reported, the Supreme Audit Agency (BPK) has examined 18 findings.

From these findings, there were 10 of which indicated fraud with a potential state loss of Rp436.87 billion.

Bio Farma President Director Shadiq Akasya uncovered 10 indications of fraud in his subsidiary, PT Indofarma Tbk.

First, there are findings of indications of losses in Indofarma's subsidiary, PT Indofarma Global Medika (IGM) worth IDR 157.33 billion for transactions of the Fast Moving Consumer Goods (FMCG) business unit.

"Then, an indication of a loss in the emergency room for the loss of deposits is approximately Rp. 35.07 billion, an indication of an emergency loss for a deposit loss of Rp. 38 billion," he said in a meeting with Commission VI of the DPR, at the DPR Building, Jakarta, Wednesday, June 19.

Ketiga, sambung Shadiq, adanya indikasi kerugian IGM atas pengadaan deposito bersama bunga senilai Rp38,06 miliar pada Bank Oke.

Then, continued Shadiq, indications of IGM losses worth Rp. 18 billion were found for the return of the down payment from MMU which did not go to the emergency room account.

"Fifth, expenditure and charge costs without being based on transactions with indications of IGM losses of IDR 24.35 billion," he explained.

Sixth, continued Shadiq, the collaboration between the TeleCTG Alkes Distribution and PT ZTI without Memadai's plan indicated a loss to IGM of IDR 4.50 billion over payments that exceeded the value of the invoice and could potentially harm IGM worth IDR 10.43 billion over TeleCTG's unsold stock.

Then, continued Shadiq, loans through fintech are not for the benefit of companies indicating a loss to IGM worth IDR 1.26 billion.

Eighth, the business activities of masks without adequate planning indicated fraud, with an indication of a loss of IDR 2.67 billion for the decrease in the value of mask supplies and a potential loss of IDR 60.24 billion for PT Promedik's bad debt and IDR 13.11 billion for the remaining supply of masks.

Ninth, the purchase and sale of the Panbio Rapid Test of PT IGM without adequate planning indicated fraud and a potential loss of Rp56.70 billion for PT Promedik's bad debt.

"Tenth, PT Indofarma carries out the purchase and sale of PCR Kit COVID-19 in 2020/2021 without adequate planning with indications of fraud and a potential loss of IDR 5.98 billion for PT Promedik traffic jams and IDR 9.17 billion for the unsold PCR Kit COVID-19," said Shadiq.